Procter & Gamble Hygiene and Health Care Ltd. Share Price

P&G Hygiene: Premium Brands & Strong Dividends

Procter & Gamble Hygiene & Health Care (PGHH) has a strong portfolio in feminine hygiene, healthcare and personal care, led by brands such as Whisper and Vicks. FY26 net profit rose 34.5%, while Q4 revenue declined 5.1% YoY and net profit fell about 2% to ₹153 crore, reflecting near-term demand and cost pressures. Latest News: The company continues to focus on premiumisation, innovation and strengthening its core brands. P&G globally expects FY27 sales growth of 1–3%, with higher input and marketing costs remaining a concern. Corporate Action: PGHH declared a ₹60/share final dividend for FY26. Earlier, it paid an interim ₹195/share, including a ₹25 special dividend. Strong brands, pricing power and exceptional dividend payouts support the long-term case, while premium valuation, weak volume growth and input-cost inflation remain key risks.

See More

announced Q1FY27 results Financial Highlights:

announced Q1FY27 results Financial Highlights: Total Income for Q1FY27 stood at Rs 90,089 lakh, representing a YoY decline of 4.64% from Rs 94,472 lakh in Q1FY26 and a QoQ decrease of 5.55% from Rs 95,379 lakh in Q4FY26. Revenue from Operations in Q1FY27 was Rs 89,146 lakh, reflecting a YoY decrease of 4.86% compared to Rs 93,703 lakh in Q1FY26 and a QoQ decline of 5.30% from Rs 94,132 lakh in Q4FY26. Profit Before Tax (PBT) for Q1FY27 was reported at Rs 16,963 lakh, down 35.92% YoY from Rs 26,470 lakh in Q1FY26 and down 22.23% QoQ from Rs 21,811 lakh in Q4FY26. Net Profit for the period reached Rs 12,627 lakh in Q1FY27, showing a YoY decline of 34.25% from Rs 19,206 lakh in Q1FY26 and a QoQ decrease of 17.54% from Rs 15,313 lakh in Q4FY26. Total Comprehensive Income for Q1FY27 was Rs 12,734 lakh, marking a 33.08% YoY decrease from Rs 19,029 lakh in Q1FY26 and a 17.21% QoQ decline from Rs 15,382 lakh in Q4FY26. Earnings Per Share (EPS) (Basic & Diluted) for Q1FY27 stood at Rs 38.90, compared to Rs 59.17 in Q1FY26 and Rs 47.17 in Q4FY26. Other Income for Q1FY27 was Rs 943 lakh, an increase from Rs 769 lakh in Q1FY26, but a decline from Rs 1,247 lakh in Q4FY26.

See More

Close crossing last Month High Strategy

Close crossing last Month High Strategy

is trading near its previous month high. • This strategy focuses on stocks that close above the previous month’s high, which often signals fresh momentum and strong buying interest. • A decisive close above this level indicates that the stock is breaking a key resistance zone,potentially starting a new upward trend. • Traders usually look for strong volume, market support, and the stock trading above important moving averages to confirm the breakout strength. • For risk management, many traders place a stop loss slightly below the breakout level while aiming to capture short to medium-term momentum moves. Disclaimer: Investments in the securities market are subject to market risks, read all the related documents carefully before investing

See More

reported INR 86 crore in productivity savings for FY 25/26 during an analyst meet. The company indexed its performance against a 12-month period following a fiscal year change from July-June to April-March. India continues to outpace global markets in GDP growth despite a slowdown. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

See More

P&G Health Limited: A Shareholder's Cash Machine

P&G Health Ltd stands as one of India's most impressive pharma companies for shareholders. The company delivers extraordinary returns with ROCE between 45-48 percent, far beating sector averages. With near-zero debt at just 0.01 debt-to-equity ratio, the firm operates without interest burden, protecting shareholder profits. Financial highlights showcase remarkable strength. Q4 FY26 saw net sales surge 50.72 percent to Rs 1,407.97 crore from Rs 934.17 crore. Net profit jumped 54.63 percent to Rs 94.60 crore. Full-year PAT climbed 39.46 percent to Rs 326.91 crore. Profit before tax rose 44.36 percent to Rs 449.86 crore. Operating cash flow nearly doubled to Rs 337.79 crore in FY26 from Rs 168.69 crore, showing powerful cash generation. For shareholders, this is highly beneficial. Company pays consistent dividends with 1.97 percent yield, returning value directly. ROE of 40.85 percent means shareholders earn excellent returns on equity. The 27.50 P/E ratio reflects quality, though premium. EPS stands at Rs 184.66 with book value of Rs 323.48 per share. Market cap Rs 10,303 crore. Zero-debt structure protects against rate hikes and stress. Strong cash flow of Rs 337 crore enables future dividends without borrowing. PAT growth of 54 percent shows operational excellence. However, concerns exist. Stock trades at 19.6 times book value, expensive. Five-year sales growth weak at 0.16 percent, though Q4 recovery. P/E of 27.50 higher than competitors. Overall, P&G Health valuable for shareholders seeking stable returns, dividends, capital preservation. High ROCE, zero debt, strong cash flow, profit growth make it quality pharma investment despite premium valuation.

See More